The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Sergio GiraltThe Multiple Myeloma Hub was pleased to speak to Sergio Giralt, Memorial Sloan Kettering Cancer Center, New York, US. We asked, Is upfront auto-stem cell transplant (SCT) still the preferred option for eligible patients?
Is upfront auto-SCT still the preferred option for eligible patients?
Giralt shares data from the IFM2009 (NCT01191060) and DETERMINATION (NCT01208662) clinical trials comparing patients who received induction therapy with and without upfront transplant. Giralt considers the latest follow-up data on progression-free survival and measurable residual disease-negativity rates between cohorts as factors, as well as the impact of individual patient factors such as preference, risk status, and age on selecting upfront auto-SCT.